ArticleAnnals of coloproctology2026
Sinus laser-assisted closure for pilonidal sinus disease: a prospective single-center study.
Article in Annals of coloproctology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePilonidal sinus disease (PSD) is a chronic condition that primarily affects young adults. Sinus laser-assisted closure (SiLaC) has recently emerged as a minimally invasive alternative to conventional surgery, offering potential benefits in postoperative recovery and recurrence rates. This study evaluates the clinical outcomes, safety, and patient satisfaction associated with SiLaC.
methodsWe conducted a retrospective analysis of prospectively collected data from 218 consecutive patients who underwent SiLaC for PSD between February 2023 and December 2024. Demographic characteristics, intraoperative parameters, postoperative complications, healing rates, and recurrence rates were examined. Pain and patient satisfaction were assessed using a standardized questionnaire.
resultsThe study cohort included 142 male patients (65.1%), with a mean age of 25.3±8.1 years. The mean operative time was 13.4±4.4 minutes, and all patients were discharged the same day. The overall complication rate was 15.1%, with most complications being minor abscesses (84.8% managed conservatively). Healing rates at 15, 30, and 45 days were 13.8%, 80.2%, and 98.1%, respectively, with a mean healing time of 26.1±9.8 days. Recurrence was observed in 8.7% of patients after a median follow-up of 11 months (range, 3-25 months), decreasing to 6.5% following a second SiLaC procedure. The mean pain score on postoperative day 1 was 2.8±2.4, and patient satisfaction at 30 days was 9.2 out of 10.
conclusionSiLaC is a safe, effective, and well-tolerated minimally invasive treatment for PSD, associated with favorable short-term outcomes, rapid recovery, and low recurrence rates. Further research is needed to optimize treatment protocols and assess long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.